Skip to main content

FDA recall, , Moderate risk

Somerset Therapeutics Dexamethasone Sodium Phosphate Injection

Dexamethasone Sodium Phosphate Injection failed impurity specifications.

What happened

Somerset Therapeutics LLC, of Somerset, New Jersey, is recalling Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only. The FDA reported the recall began on February 4, 2026, and was added to its Enforcement Report on March 19, 2026.

The product failed impurity specifications, as an out-of-specification impurities result was observed during long term stability testing at product expiry (24 months) for Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.

The product was distributed nationwide in the USA. The recall involves 62190 vials.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

Match the lot code and NDC listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Dexamethasone Sodium Phosphate Injection, USP

    Strength
    100 mg
    Lot code
    • A240421
    Recall number
    D-0398-2026
  2. NDC
    • 70069-025-10
    • 70069-025-01

Recall details

Company began the recall
Sold in

Nationwide in the USA

Company
SOMERSET THERAPEUTICS LLCSomerset, New Jersey
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
98388
Recall number
D-0398-2026
Quantity recalled
62190 vials

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Classified by FDA

  3. Added to FDA's Enforcement Report

  4. In FDA's weekly enforcement report

  5. Listed on Recall Canary

  6. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 3, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)